Treatment with the clinical candidate, obeticholic acid reversed the hepatic steatosis phenotype and transcriptomic analysis confirmed the selective activation of FXR target genes including upregulation of FGF19 and PLIN1 and downregulation of SLC51B and CYP7A1 genes by OCA. The gene discussed is CYP7A1; the disease is fatty liver disease.